famotidine has been researched along with Stomach Neoplasms in 14 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to compare the effects of omeprazole and famotidine on ulcer healing and fibroblast growth factor-2 levels in gastric ulcers induced by endoscopic mucosal resection." | 9.10 | Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. ( Aoyagi, K; Esaki, M; Fujishima, M; Kuwano, Y; Matsumoto, T; Shimizu, M, 2002) |
| "A total of 158 patients (155 early gastric cancers and three adenomas) were randomly assigned to the PPI group (omeprazole 20 mg/day) or H(2) RA group (famotidine 40 mg/day) in a prospective randomized controlled trial." | 5.16 | Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. ( Fukui, H; Hori, K; Kim, Y; Kondo, T; Matsumoto, T; Miwa, H; Morita, T; Okugawa, T; Oshima, T; Sakurai, J; Tanaka, J; Tomita, T; Toyoshima, F; Watari, J; Yamasaki, T, 2012) |
| " This study aimed to compare the effects of omeprazole and famotidine on ulcer healing and fibroblast growth factor-2 levels in gastric ulcers induced by endoscopic mucosal resection." | 5.10 | Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. ( Aoyagi, K; Esaki, M; Fujishima, M; Kuwano, Y; Matsumoto, T; Shimizu, M, 2002) |
| " Subjects underwent EMR with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate (EMRSH), followed by IV or oral (PO) administration of famotidine at a dosage of 40 mg/day for 2 days." | 2.71 | Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. ( Ajibe, H; Hanatsuka, K; Hirasawa, T; Kawata, H; Kita, H; Osawa, H; Satoh, K; Satoh, Y; Sugano, K; Sunada, F; Sunada, K; Yamamoto, H; Yoshizawa, M, 2005) |
| "Subjects with gastric cancer showed significantly higher levels of suppressor lymphocyte activity than normal controls." | 1.29 | Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. ( Hahm, KB; Kang, JK; Kim, WH; Lee, SI; Park, IS, 1995) |
| "Famotidine has no action on membrane components activating the adenylate cyclase system, including the Gs subunit of the enzyme stimulated by forskolin and cell surface receptors sensitive to isoproterenol (beta 2-type), PGE2 and VIP." | 1.28 | Pharmacological control of the human gastric histamine H2 receptor by famotidine: comparison with H1, H2 and H3 receptor agonists and antagonists. ( Emami, S; Fagot, D; Gespach, C, 1989) |
| "In the HGT-1 human gastric cancer cell line, famotidine and ranitidine showed long lasting, irreversible actions probably related to a slow rate of dissociation from the histamine H2-receptor." | 1.27 | Pharmacological control of the histamine H2 receptor-adenylate cyclase system by famotidine and ranitidine in normal and cancerous human gastric epithelia. ( Bawab, W; Chastre, E; Emami, S; Fagot, D; Gespach, C, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 1 |
| Fan, P | 1 |
| Liu, M | 1 |
| Weng, C | 1 |
| Fan, G | 1 |
| Zhang, T | 1 |
| Duan, X | 1 |
| Wu, Y | 1 |
| Tang, L | 1 |
| Yang, G | 1 |
| Liu, Y | 1 |
| Tomita, T | 1 |
| Kim, Y | 1 |
| Yamasaki, T | 1 |
| Okugawa, T | 1 |
| Kondo, T | 1 |
| Toyoshima, F | 1 |
| Sakurai, J | 1 |
| Tanaka, J | 2 |
| Morita, T | 1 |
| Oshima, T | 1 |
| Fukui, H | 1 |
| Hori, K | 1 |
| Watari, J | 1 |
| Matsumoto, T | 2 |
| Miwa, H | 1 |
| Yamaguchi, Y | 1 |
| Katsumi, N | 1 |
| Tauchi, M | 1 |
| Toki, M | 1 |
| Nakamura, K | 1 |
| Aoki, K | 1 |
| Morita, Y | 1 |
| Miura, M | 1 |
| Morozumi, K | 1 |
| Ishida, H | 1 |
| Takahashi, S | 1 |
| Satoh, K | 1 |
| Yamamoto, H | 1 |
| Kawata, H | 1 |
| Osawa, H | 1 |
| Hanatsuka, K | 1 |
| Kita, H | 1 |
| Sunada, K | 1 |
| Hirasawa, T | 1 |
| Yoshizawa, M | 1 |
| Ajibe, H | 1 |
| Satoh, Y | 1 |
| Sunada, F | 1 |
| Sugano, K | 1 |
| Ye, BD | 1 |
| Cheon, JH | 1 |
| Choi, KD | 1 |
| Kim, SG | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Jeong, HK | 1 |
| Park, CH | 1 |
| Jun, CH | 1 |
| Lee, GH | 1 |
| Kim, HI | 1 |
| Kim, HS | 1 |
| Choi, SK | 1 |
| Rew, JS | 1 |
| Hahm, KB | 1 |
| Kim, WH | 1 |
| Lee, SI | 1 |
| Kang, JK | 1 |
| Park, IS | 1 |
| Fujimoto, K | 1 |
| Iwakiri, R | 1 |
| Koyama, T | 1 |
| Sakata, H | 1 |
| Ohyama, T | 1 |
| Mizuguchi, M | 1 |
| Tokunaga, O | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Dogăn, UB | 1 |
| Tunçer, C | 1 |
| Dursun, A | 1 |
| Kandilci, U | 1 |
| Esaki, M | 1 |
| Aoyagi, K | 1 |
| Kuwano, Y | 1 |
| Shimizu, M | 1 |
| Fujishima, M | 1 |
| Isobe, Y | 1 |
| Nagai, H | 1 |
| Muramatsu, M | 1 |
| Aihara, H | 1 |
| Otomo, S | 1 |
| Gespach, C | 2 |
| Fagot, D | 2 |
| Emami, S | 2 |
| Chastre, E | 1 |
| Bawab, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for famotidine and Stomach Neoplasms
| Article | Year |
|---|---|
Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection.
Topics: Adenocarcinoma; Adenoma; Aged; Aged, 80 and over; Analysis of Variance; Famotidine; Female; Gastric | 2012 |
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.
Topics: Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Endoscopy, Gastrointestinal; Famotidine; Female; Gas | 2005 |
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Endoscopy, Gastrointestinal; Fam | 2005 |
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Hum | 2006 |
A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Dissection; Famotidine; Female; Ga | 2007 |
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans.
Topics: Aged; Anti-Ulcer Agents; Endoscopy; Famotidine; Female; Fibroblast Growth Factor 2; Humans; Male; Mi | 2002 |
8 other studies available for famotidine and Stomach Neoplasms
| Article | Year |
|---|---|
Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells.
Topics: Anti-Ulcer Agents; Cell Line, Tumor; Famotidine; Histamine H2 Antagonists; Humans; Inflammasomes; In | 2021 |
Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cimetidine; Cytotoxicity Tests, Immunologic; Famotidin | 1995 |
Hyperplastic polyps following treatment of acute gastric ulcers.
Topics: Esophageal and Gastric Varices; Famotidine; Female; Humans; Hyperplasia; Middle Aged; Omeprazole; Po | 1994 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
Effect of chronic acid inhibition on duodenal bulb gastric metaplasia and Helicobacter pylori.
Topics: Adult; Case-Control Studies; Duodenal Ulcer; Duodenum; Famotidine; Female; Gastric Mucosa; Helicobac | 1998 |
Antisecretory and antilesional effect of a new histamine H2-receptor antagonist, IT-066, in rats.
Topics: Animals; Cimetidine; Cold Temperature; Cysteamine; Dose-Response Relationship, Drug; Duodenal Neopla | 1990 |
Pharmacological control of the human gastric histamine H2 receptor by famotidine: comparison with H1, H2 and H3 receptor agonists and antagonists.
Topics: Adenylyl Cyclases; Cyclic AMP; Famotidine; Gastric Fundus; Histamine; Histamine H2 Antagonists; Huma | 1989 |
Pharmacological control of the histamine H2 receptor-adenylate cyclase system by famotidine and ranitidine in normal and cancerous human gastric epithelia.
Topics: Adenylyl Cyclases; Epithelium; Famotidine; Gastric Fundus; Humans; In Vitro Techniques; Ranitidine; | 1988 |